Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) has earned an average broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and one has given a strong buy rating to the company.

Brokerages have set a twelve-month consensus price target of $19.00 for the company, according to Zacks. Zacks has also assigned Osmotica Pharmaceuticals an industry rank of 93 out of 257 based on the ratings given to related companies.

A number of equities research analysts recently commented on OSMT shares. Jefferies Financial Group started coverage on Osmotica Pharmaceuticals in a research report on Monday. They issued a “buy” rating for the company. Wells Fargo & Co initiated coverage on Osmotica Pharmaceuticals in a research note on Monday. They issued an “outperform” rating and a $18.00 price objective for the company. Finally, Royal Bank of Canada initiated coverage on Osmotica Pharmaceuticals in a research note on Monday. They issued an “outperform” rating and a $17.00 price objective for the company.

NASDAQ OSMT traded down $0.86 on Tuesday, reaching $7.66. The company had a trading volume of 59,606 shares, compared to its average volume of 67,750. Osmotica Pharmaceuticals has a 52-week low of $7.03 and a 52-week high of $9.90.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods.

Featured Story: Are Wall Street analysts’ stock ratings worth following?

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.